BioSyent Inc
Joost van der Mark has held various leadership positions in the pharmaceutical industry, including as the Founder & CEO of Orphan Canada Inc. Joost has experience in corporate development, business strategy, and commercial planning. Joost has a strong track record of successfully in-licensing pharmaceutical products and building successful companies. Joost has an MBA in Strategic Marketing & Finance from Schulich School of Business, York University, and an MSc in Physiology/Pharmacology from Western University.
BioSyent Inc
1 followers
Listed on the TSX Venture Exchange (TSXV: RX) BioSyent is a profitable growth oriented speciality pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are proven safe and effective, and have track records of improving the lives of patients and supporting the healthcare professionals that treat them. Once a product of interest has been found, BioSyent acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada. BioSyent continues to search for products to in-license or acquire that match the following criteria: - Are unique and occupy a niche in the market; - Provide novel technological or therapeutic advantages to patients and healthcare professionals; - Are backed by strong partners who hold defendable intellectual property rights. Backed by the success of our products, for two consecutive years (2012 & 2013) BioSyent was named to the TSX Venture Top 50 strong performing companies. BioSyent has been named one of Canada’s fastest growing companies by PROFIT Magazine.